Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ERGONASDAQ:GRINASDAQ:HCMNASDAQ:INDV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERGOEntia Biosciences$0.00$0.00▼$0.00N/A12.3150 shsN/AGRIGRI Bio$1.35+3.8%$1.50$1.10▼$59.33$2.89M-1.68289,011 shs43,661 shsHCMHUTCHMED$16.76-0.9%$14.35$11.51▼$21.50$2.92B0.5299,741 shs15,024 shsINDVIndivior$14.10+1.5%$11.30$7.33▼$16.98$1.95B0.661.10 million shs461,010 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERGOEntia Biosciences0.00%0.00%0.00%0.00%0.00%GRIGRI Bio0.00%-5.80%-13.33%-76.87%-97.42%HCMHUTCHMED0.00%+10.10%+26.21%+11.62%-6.73%INDVIndivior0.00%-1.28%+22.49%+39.04%-15.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERGOEntia BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AGRIGRI Bio2.0602 of 5 stars3.52.00.00.01.90.01.3HCMHUTCHMED1.439 of 5 stars2.02.00.00.02.80.01.9INDVIndivior2.5673 of 5 stars1.65.00.00.03.41.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERGOEntia Biosciences 0.00N/AN/AN/AGRIGRI Bio 3.00Buy$22.001,529.63% UpsideHCMHUTCHMED 2.00Hold$19.0013.39% UpsideINDVIndivior 3.25Buy$15.006.35% UpsideCurrent Analyst Ratings BreakdownLatest ERGO, HCM, INDV, and GRI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/27/2025GRIGRI BioAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $34.005/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold4/14/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERGOEntia BiosciencesN/AN/AN/AN/AN/AN/AGRIGRI BioN/AN/AN/AN/A$5.22 per shareN/AHCMHUTCHMED$630.20M4.63$0.68 per share24.51$4.27 per share3.92INDVIndivior$1.17B1.66$2.86 per share4.94N/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERGOEntia BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/AGRIGRI Bio-$13.04M-$11.56N/AN/AN/AN/A-289.05%-165.01%8/12/2025 (Estimated)HCMHUTCHMED$100.78MN/A0.0011.48N/AN/AN/AN/A6/18/2025 (Estimated)INDVIndivior$2M-$0.31N/A8.25N/A-3.96%-241.73%15.09%7/24/2025 (Estimated)Latest ERGO, HCM, INDV, and GRI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GRIGRI Bio-$4.08-$5.80-$1.72-$5.80N/AN/A4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERGOEntia BiosciencesN/AN/AN/AN/AN/AGRIGRI Bio$1.91141.48%N/AN/A N/AHCMHUTCHMEDN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERGOEntia BiosciencesN/AN/AN/AGRIGRI BioN/A3.103.10HCMHUTCHMED0.072.812.68INDVIndiviorN/A0.830.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERGOEntia BiosciencesN/AGRIGRI Bio33.95%HCMHUTCHMED8.82%INDVIndivior60.33%Insider OwnershipCompanyInsider OwnershipERGOEntia Biosciences28.30%GRIGRI Bio0.13%HCMHUTCHMED3.60%INDVIndiviorN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERGOEntia Biosciences6N/AN/ANot OptionableGRIGRI Bio12.14 million8.92 millionNot OptionableHCMHUTCHMED1,760174.32 million168.04 millionNot OptionableINDVIndivior1,164137.88 millionN/ANot OptionableERGO, HCM, INDV, and GRI HeadlinesRecent News About These CompaniesPromising Cannabis Stocks Worth Watching - June 8thJune 8, 2025 | marketbeat.comPiper Sandler Keeps Their Buy Rating on Indivior (INDV)June 8, 2025 | theglobeandmail.comTop Cannabis Stocks To Keep An Eye On - June 7thJune 7, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Grows Stock Position in Indivior PLC (NASDAQ:INDV)June 7, 2025 | marketbeat.comCannabis Stocks To Consider - June 6thJune 6, 2025 | marketbeat.comPromising Cannabis Stocks To Follow Today - June 5thJune 5, 2025 | marketbeat.comIndivior (NASDAQ:INDV) Shares Gap Down - What's Next?June 3, 2025 | marketbeat.comPromising Cannabis Stocks To Add to Your Watchlist - June 1stJune 2, 2025 | marketbeat.comIndivior brings curtain down on turbulent 11-year run in LondonJune 2, 2025 | proactiveinvestors.co.ukIndivior to delist from London Stock Exchange, maintain Nasdaq listingJune 2, 2025 | reuters.comCannabis Stocks To Add to Your Watchlist - May 31stJune 1, 2025 | marketbeat.comIndivior (NASDAQ:INDV) Trading 3.8% Higher - What's Next?May 31, 2025 | marketbeat.comMan Group plc Grows Holdings in Indivior PLC (NASDAQ:INDV)May 27, 2025 | marketbeat.comInvestors in Indivior (LON:INDV) have seen solid returns of 156% over the past five yearsMay 26, 2025 | uk.finance.yahoo.comMillennium Management LLC Grows Position in Indivior PLC (NASDAQ:INDV)May 25, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Takes Position in Indivior PLC (NASDAQ:INDV)May 25, 2025 | marketbeat.comBank of America Corp DE Sells 401,697 Shares of Indivior PLC (NASDAQ:INDV)May 24, 2025 | marketbeat.comGotham Asset Management LLC Acquires New Holdings in Indivior PLC (NASDAQ:INDV)May 23, 2025 | marketbeat.comDeutsche Bank AG Has $3.59 Million Stake in Indivior PLC (NASDAQ:INDV)May 23, 2025 | marketbeat.comIndivior PLC (NASDAQ:INDV) Shares Sold by Two Seas Capital LPMay 23, 2025 | marketbeat.comState of Wyoming Sells 36,106 Shares of Indivior PLC (NASDAQ:INDV)May 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeERGO, HCM, INDV, and GRI Company DescriptionsEntia Biosciences OTCMKTS:ERGOEntia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.GRI Bio NASDAQ:GRI$1.35 +0.05 (+3.85%) As of 11:30 AM EasternGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.HUTCHMED NASDAQ:HCM$16.76 -0.14 (-0.85%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Indivior NASDAQ:INDV$14.10 +0.21 (+1.54%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year AMD Accelerates Stack Development: Share Price to Follow Alphabet Enters a Bull Market: Is It Time to Buy? Micron Joins Latest $200 Billion United States Investment Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Tariff Talks Advance, What Taiwan Semiconductor Can Deliver Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
